Your Messages Inbox
Your Article Summary
See Latest ArticlesWarner Chilcott Reports Operating Results for the Quarter Ended March 31, 2009 and Updates 2009 Full Year Guidance
Warner Chilcott, 07/30/09
Warner Chilcott Limited announced its results for the quarter ended March 2009. Revenue in the quarter ended March 2009 totaled $246.0 million, an increase of 7.2% over the prior year quarter. The primary drivers of the increase in revenue were the net sales of DORYX, LOESTRIN 24 FE and ESTRACE CREAM, which together contributed $24.8 million of revenue growth for the quarter ended March 2009, as compared to the prior year quarter. The growth delivered by these products was partially offset by net sales declines in certain other products, primarily DOVONEX and FEMHRT.
Today in Financial Reports...keeping you current
Receive free subspecialty "5-minute updates" via email
HP to Acquire Networking Firm 3Com
HealthDataManagement, 11/20/09
Protox Reports 2009 Third Quarter Results
Protox Therapeutics , 11/18/09
King Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference
King Pharmaceuticals, 11/16/09
Article Search
Sponsor